Market capitalization | €1.61b |
Enterprise Value | €-1.53b |
P/E (TTM) P/E ratio | 21.88 |
EV/FCF (TTM) EV/FCF | 4.99 |
EV/Sales (TTM) EV/Sales | -5.56 |
P/S ratio (TTM) P/S ratio | 5.86 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue (TTM) Revenue | €275.65m |
EBIT (operating result TTM) EBIT | €-229.11m |
As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.
12 Analysts have issued a Galapagos forecast:
12 Analysts have issued a Galapagos forecast:
Dec '24 |
+/-
%
|
||
Revenue | 276 276 |
-
|
|
Gross Profit | 241 241 |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -229 -229 |
-
|
Net Profit | 74 74 |
-
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.